Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Completed 30 enrolled Klinikum Ludwigshafen Coordination center for clinical studies, Mainz, Germany · collab Norvartis Pharma, Nuremberg, Germany · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.

Timeline

Start: 2007-11
Primary completion: 2010-09
Completion: 2010-09

Publications

Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb C, Junker B, Schaefer C, Zwiener I, Hattenbach LO; RABAMES Study Group. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol. 2015 Feb;93(1):e29-37. doi: 10.1111/aos.12488. Epub 2014 Jul 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Summary

Timeline

Publications

Drugs

Indications